En esta página
01BOLT precio
02Instantánea
03Gráfico
04Divisiones de acciones
06Rendimiento
07Valoración y ratios
14Ganancias
15Fundamentales Completos
16Estados Financieros
17Propietarios institucionales (13F)
18Activistas y propietarios del %+ 5
19Informantes de la empresa
20Propiedad de ETFs
21Consenso
22Pares
23Noticias
26Mis Métricas
BOLT Bolt Biotherapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 11, 2026
$3,45
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$3,10mínimo 52 semanas
$7,01máximo 52 semanas
Capitalización Bursátil (MRQ)
$7M
P/E (TTM)
-0.2
BPA (TTM)
$-21.98
Ingresos (TTM)
$5M
tus insignias
Rango 52S
$3–$7
Calificación del Analista
BUY
Precio Objetivo
$29
P/E
-0.2
ROE
-111.6%
Margen de Beneficio Neto
-611.5%
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
BOLT Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$3.45
Capitalización Bursátil (MRQ)
$7M
P/E (TTM)
-0.2
BPA (TTM)
$-21.98
Ingresos (TTM)
$5M
ROE (TTM)
-111.6%
Rango 52S
$3–$7
BOLT Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Divisiones de acciones
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 9 de junio de 2025 | 1-for-20 | Inversa |
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos$8M2020-12-31 → 2025-12-31
BPA$-17.852021-12-31 → 2025-12-31
Flujo de caja libre$-40M2021-12-31 → 2025-12-31
Margen neto-611.5%2021-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | BOLT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | -0.2promedio 5A ≈-11.4 | ≈-11.4 | · | · | |
| P/S (TTM) | 1.4promedio 5A ≈648.7 | ≈648.7 | 1.8 | Valor razonable | |
| P/C (MRQ) | 0.5promedio 5A ≈7.1 | ≈7.1 | 1.0 | Infravalorado | |
| Price / FCF (Precio / FCF) | -0.2promedio 5A ≈-18.7 | ≈-18.7 | · | · | |
| Price / Cash Flow (Precio / Flujo de Caja) | -0.2promedio 5A ≈-19.3 | ≈-19.3 | · | · | |
| Price / Tangible Book (Precio / Valor Contable Tangible) | 0.2promedio 5A ≈7.1 | ≈7.1 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | BOLT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Operativo (TTM) | -654.5%promedio 5A ≈-2265.5% | ≈-2265.5% | -51300.8% | Débil | |
| Margen EBITDA (TTM) | -635.0%promedio 5A ≈-2228.0% | ≈-2228.0% | -51300.8% | Débil | |
| Pretax Margin (Margen antes de impuestos) | -433.7% | · | · | · | |
| Margen de Beneficio Neto (TTM) | -611.5%promedio 5A ≈-2299.1% | ≈-2299.1% | -50068.8% | Débil | |
| ROA (TTM) | -49.6%promedio 5A ≈-43.1% | ≈-43.1% | -96.7% | De primer nivel | |
| ROE (TTM) | -111.6%promedio 5A ≈-68.8% | ≈-68.8% | -138.9% | De primer nivel | |
| ROIC | -136.2% | · | · | · |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | BOLT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 2.6promedio 5A ≈5.7 | ≈5.7 | 2.5 | En línea | |
| Quick Ratio (Ratio Rápido) | 3.3promedio 5A ≈5.5 | ≈5.5 | 3.0 | Por debajo del promedio |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | BOLT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | 0.07%promedio 5A ≈167.1% | ≈167.1% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | 10.3%promedio 5A ≈105.8% | ≈105.8% | · | · | |
| Revenue CAGR 5Y (Ingresos CAGR 5A) | 101.6% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | BOLT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.1promedio 5A ≈0.0 | ≈0.0 | 0.2 | Débil | |
| Revenue / Employee (Ingresos / Empleado) | ≈$334.6K | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
7.2%
Próximo informe
Nov 10, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 12, 2026 | $-4.57 | $-3.45 | -32.3% |
| 31 de marzo de 2026 | May 11, 2026 | $-4.31 | $-2.91 | -48.3% |
| 31 de diciembre de 2025 | $-3.84 | $-6.23 | 38.4% | |
| 30 de septiembre de 2025 | $-3.72 | $-5.90 | 37.0% | |
| 30 de junio de 2025 | $-4.46 | $-6.58 | 32.2% | |
| 31 de marzo de 2025 | $-5.80 | $-7.39 | 21.6% | |
| 31 de diciembre de 2024 | $-7.60 | $-7.75 | 2.0% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $8M | $8M | $8M | $6M | $1M | $231.0K | |
| R&D Expense | $29M | $57M | $62M | $73M | $76M | $40M | |
| SG&A Expense | $14M | $18M | $23M | $23M | $18M | $9M | |
| Operating Expenses | $44M | $81M | $84M | $96M | $94M | $49M | |
| Operating Income | $-36M | $-73M | $-76M | $-90M | $-93M | $-49M | |
| Other Non-op | $3M | $10M | $7M | $2M | $-6M | $-12M | |
| Pretax Income | $-33M | $-63M | · | · | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-33M | $-63M | $-69M | $-88M | $-99M | $-61M | |
| EPS (Basic) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | · | |
| EPS (Diluted) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | · | |
| Shares (Basic) | 1,869,924 | 1,909,225 | 37,811,984 | 37,358,425 | 33,196,712 | 1,989,208 | |
| Shares (Diluted) | 1,869,924 | 1,909,225 | 37,811,984 | 37,358,425 | 33,196,712 | · | |
| EBITDA | $-35M | $-71M | $-74M | $-89M | $-92M | · |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12M | $7M | $11M | $9M | $27M | $6M | |
| Short-term Investments | $16M | $40M | $91M | $160M | $159M | $17M | |
| Prepaid Expense | $3M | $3M | $4M | $4M | $3M | $3M | |
| Current Assets | $30M | $51M | $106M | $173M | $189M | $25M | |
| PP&E (Net) | $1M | $3M | $5M | $6M | $6M | $4M | |
| PP&E (Gross) | $9M | $10M | $11M | $10M | $8M | $5M | |
| Accum. Depreciation | $7M | $7M | $6M | $4M | $2M | $1M | |
| Other Non-current Assets | $138.0K | $62.0K | $2M | $1M | $1M | $909.0K | |
| Total Assets | $57M | $100M | $160M | $228M | $308M | $47M | |
| Accounts Payable | $1M | $2M | $3M | $4M | $4M | $2M | |
| Current Liabilities | $8M | $16M | $20M | $23M | $21M | $11M | |
| Capital Leases | $20M | $23M | $17M | $20M | $22M | $9M | |
| Other Non-current Liabilities | $132.0K | $0 | $43.0K | $42.0K | $210.0K | $329.0K | |
| Total Liabilities | $30M | $42M | $47M | $56M | $58M | $46M | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | · | |
| Retained Earnings | $-461M | $-427M | $-364M | $-295M | $-207M | $-108M | |
| AOCI | $-21.0K | $97.0K | $37.0K | $-919.0K | $-321.0K | · | |
| Stockholders' Equity | $27M | $57M | $113M | $172M | $250M | $-105M | |
| Liabilities + Equity | $57M | $100M | $160M | $228M | $308M | $47M | |
| Shares Outstanding | 1,920,566 | 1,916,943 | 38,114,606 | 37,797,902 | 37,399,694 | 2,130,139 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $1M | $2M | $2M | $2M | $1M | $611.0K | |
| Stock-based Comp | $3M | $7M | $9M | $10M | $8M | $1M | |
| Restructuring | $1M | $3M | $0 | · | · | · | |
| Other Non-cash | $-11M | $-7M | $-11M | $352.0K | $32M | · | |
| Operating Cash Flow | $-40M | $-61M | $-70M | $-77M | $-57M | $-47M | |
| CapEx | $72.0K | $41.0K | $206.0K | $2M | $2M | $3M | |
| Investing Cash Flow | $44M | $58M | $71M | $58M | $-232M | $-21M | |
| Stock Issued | $19.0K | $108.0K | $253.0K | $503.0K | $1M | $294.0K | |
| Net Stock Activity | $19.0K | $108.0K | $253.0K | $503.0K | $1M | · | |
| Financing Cash Flow | $19.0K | $108.0K | $253.0K | $503.0K | $311M | $40M | |
| Net Change in Cash | $4M | $-4M | $2M | $-18M | $22M | $-28M | |
| Free Cash Flow | $-40M | $-61M | $-70M | $-78M | $-59M | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -469.3% | -949.9% | -967.5% | -1576.6% | -7364.1% | · | |
| Net Margin | -433.7% | -820.8% | -878.6% | -1537.8% | -7824.7% | · | |
| Pretax Margin | -433.7% | · | · | · | · | · | |
| EBITDA Margin | -452.5% | -926.8% | -943.9% | -1547.5% | -7269.4% | · | |
| ROA | -42.7% | -48.7% | -35.7% | -32.9% | -55.7% | · | |
| ROE | -102.2% | -97.7% | -57.4% | -48.9% | -37.6% | · | |
| ROIC | -136.2% | · | · | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.2 | 5.2 | 7.5 | 8.9 | · | |
| Quick Ratio | 3.3 | 3.0 | 5.0 | 7.3 | 8.7 | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $13.80 | $1.49 | $2.96 | $4.54 | $6.69 | · | |
| Revenue / Share | $4.12 | $0.20 | $0.21 | $0.15 | · | · | |
| Cash Flow / Share | $-21.31 | $-1.61 | $-1.84 | $-2.05 | · | · | |
| Cash / Share | $6.09 | $0.19 | $0.28 | $0.24 | $0.73 | · | |
| EPS (TTM) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | · |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | 0.07% | -2.4% | 37.5% | 354.7% | 445.5% | · | |
| Revenue CAGR 3Y | 10.3% | 82.8% | 224.3% | · | · | · | |
| Revenue CAGR 5Y | 101.6% | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $8M | $8M | $6M | $1M | $231.0K | |
| Net Income TTM | $-33M | $-63M | $-69M | $-88M | $-99M | $-61M | |
| Market Cap | $11M | $410M | $854M | $983M | $3.67B | · | |
| P/E | -0.3 | -0.3 | -12.2 | -11.0 | -33.0 | · | |
| P/S | 1.4 | 53.3 | 108.4 | 171.5 | 2908.9 | · | |
| P/B | 0.4 | 7.2 | 7.6 | 5.7 | 14.7 | · | |
| P / Tangible Book | 0.4 | 7.2 | 7.6 | 5.7 | 14.7 | · | |
| P / Cash Flow | -0.3 | -6.7 | -12.3 | -12.8 | -64.2 | · | |
| P / FCF | -0.3 | -6.7 | -12.2 | -12.5 | -61.7 | · | |
| Earnings Yield | -326.4% | -309.0% | -8.2% | -9.1% | -3.0% | · |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $26.0K | $2M | $2M | $2M | $1M | $0 | $1M | $1M | $5M | $2M | $3M | $1M | $2M | $1M | $2M | |
| R&D Expense | $5M | $5M | $5M | $7M | $7M | $10M | $12M | $14M | $15M | $17M | $16M | $15M | $16M | $15M | $17M | $19M | |
| SG&A Expense | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $5M | |
| Operating Expenses | $8M | $8M | $10M | $10M | $11M | $13M | $17M | $18M | $24M | $22M | $22M | $21M | $21M | $20M | $22M | $24M | |
| Operating Income | $-8M | $-8M | $-7M | $-8M | $-9M | $-12M | $-17M | $-16M | $-23M | $-17M | $-20M | $-18M | $-20M | $-18M | $-21M | $-22M | |
| Other Non-op | $654.0K | $357.0K | $454.0K | $559.0K | $649.0K | $1M | $980.0K | $1M | $1M | $6M | $2M | $2M | $2M | $1M | $1M | $587.0K | |
| Net Income | $-8M | $-7M | $-7M | $-7M | $-9M | $-11M | $-16M | $-15M | $-21M | $-11M | $-18M | $-16M | $-18M | $-17M | $-20M | $-22M | |
| EPS (Basic) | $-4.57 | $-4.31 | $-9.38 | $-3.72 | $-4.46 | $-5.76 | $-13.73 | $-7.93 | $-11.12 | $-0.28 | $-0.47 | $-0.43 | $-0.48 | $-0.45 | $-0.53 | $-0.58 | |
| EPS (Diluted) | $-4.57 | $-4.31 | $-9.38 | $-3.72 | $-4.46 | $-5.76 | $-13.73 | $-7.93 | $-11.12 | $-0.28 | $-0.47 | $-0.43 | $-0.48 | $-0.45 | $-0.53 | $-0.58 | |
| Shares (Basic) | 1,690,529 | 1,680,445 | · | 1,919,441 | 1,917,629 | 1,916,943 | · | 1,912,554 | 1,906,496 | 38,068,424 | · | 37,868,480 | 37,750,393 | 37,684,023 | · | 37,454,340 | |
| Shares (Diluted) | 1,690,529 | 1,680,445 | · | 1,919,441 | 1,917,629 | 1,916,943 | · | 1,912,554 | 1,906,496 | 38,068,424 | · | 37,868,480 | 37,750,393 | 37,684,023 | · | 37,454,340 | |
| EBITDA | $-8M | $-7M | · | $-8M | $-9M | $-12M | · | $-16M | $-23M | $-17M | · | $-18M | $-20M | $-18M | · | · |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13M | $12M | $12M | $18M | $10M | $8M | $7M | $9M | $6M | $4M | $11M | $9M | $13M | $15M | $9M | $11M | |
| Short-term Investments | $5M | $11M | $16M | $14M | $25M | $30M | $40M | $44M | $67M | $87M | $91M | $111M | $112M | $112M | $160M | $161M | |
| Prepaid Expense | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $6M | $5M | $5M | $4M | $4M | |
| Current Assets | $21M | $26M | $30M | $36M | $38M | $43M | $51M | $57M | $77M | $95M | $106M | $125M | $131M | $132M | $173M | $175M | |
| PP&E (Net) | $571.0K | $1M | $1M | $2M | $2M | $2M | $3M | $4M | $4M | $4M | $5M | $5M | $6M | $6M | $6M | $7M | |
| PP&E (Gross) | $4M | $9M | $9M | $9M | $9M | $9M | $10M | $10M | $11M | $11M | $11M | $11M | $10M | $10M | $10M | $10M | |
| Accum. Depreciation | $4M | $8M | $7M | $7M | $7M | $6M | $7M | $7M | $7M | $6M | $6M | $5M | $5M | $4M | $4M | $3M | |
| Other Non-current Assets | $87.0K | $112.0K | $138.0K | $179.0K | $222.0K | $51.0K | $62.0K | $287.0K | $308.0K | $2M | $2M | $1M | $1M | $1M | $1M | $1M | |
| Total Assets | $40M | $48M | $57M | $65M | $75M | $86M | $100M | $109M | $124M | $143M | $160M | $175M | $191M | $206M | $228M | $246M | |
| Accounts Payable | $868.0K | $2M | $1M | $2M | $2M | $2M | $2M | $1M | $3M | $2M | $3M | $4M | $3M | $2M | $4M | $4M | |
| Current Liabilities | $8M | $7M | $8M | $10M | $12M | $14M | $16M | $18M | $18M | $17M | $20M | $19M | $18M | $16M | $23M | $24M | |
| Capital Leases | $19M | $19M | $20M | $21M | $22M | $22M | $23M | $15M | $16M | $17M | $17M | $18M | $19M | $20M | $20M | $21M | |
| Other Non-current Liabilities | $132.0K | $158.0K | $132.0K | $133.0K | $133.0K | $132.0K | $0 | $0 | $0 | $0 | $43.0K | $43.0K | $43.0K | $43.0K | $42.0K | $200.0K | |
| Total Liabilities | $28M | $28M | $30M | $33M | $37M | $39M | $42M | $37M | $38M | $39M | $47M | $47M | $49M | $48M | $56M | $57M | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.0K | $1.0K | $1.0K | $0 | $1.0K | $1.0K | $0 | $0 | $0 | |
| Retained Earnings | $-476M | $-468M | $-461M | $-454M | $-447M | $-438M | $-427M | $-411M | $-396M | $-375M | $-364M | $-346M | $-330M | $-312M | $-295M | $-275M | |
| AOCI | $-44.0K | $-11.0K | $-21.0K | $-10.0K | $-6.0K | $40.0K | $97.0K | $205.0K | $-44.0K | $-36.0K | $37.0K | $-174.0K | $-229.0K | $-235.0K | $-919.0K | $-2M | |
| Stockholders' Equity | $13M | $20M | $27M | $32M | $39M | $47M | $57M | $72M | $86M | $104M | $113M | $128M | $142M | $158M | $172M | $188M | |
| Liabilities + Equity | $40M | $48M | $57M | $65M | $75M | $86M | $100M | $109M | $124M | $143M | $160M | $175M | $191M | $206M | $228M | $246M | |
| Shares Outstanding | 1,926,345 | 1,921,567 | 1,920,566 | 1,919,441 | 1,919,441 | 38,339,697 | 1,916,943 | 38,273,002 | 38,264,843 | 38,127,740 | 38,114,606 | 37,965,870 | 37,950,986 | 37,813,037 | 37,797,902 | 37,660,893 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $171.0K | $203.0K | $255.0K | $290.0K | $347.0K | $399.0K | $426.0K | $440.0K | $457.0K | $458.0K | $467.0K | $462.0K | $458.0K | $467.0K | $462.0K | $439.0K | |
| Stock-based Comp | $552.0K | $545.0K | $1M | $407.0K | $625.0K | $709.0K | $1M | $1M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Restructuring | · | · | $1M | $0 | $0 | · | $-222.0K | $0 | $4M | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-2M | · | · | · | $-3M | · | · | · | $-9M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $-7M | $-8M | $-7M | $-10M | $-10M | $-13M | $-14M | $-14M | $-16M | $-17M | $-14M | $-17M | $-15M | $-23M | $-18M | $-13M | |
| CapEx | · | · | $0 | $72.0K | · | · | $0 | $41.0K | $0 | $0 | $6.0K | $165.0K | $32.0K | $3.0K | $184.0K | $735.0K | |
| Investing Cash Flow | $8M | $8M | $1M | $18M | $11M | $15M | $12M | $17M | $18M | $10M | $16M | $13M | $14M | $29M | $16M | $1M | |
| Stock Issued | $19.0K | $6.0K | $5.0K | $0 | $14.0K | $0 | $29.0K | $0 | · | · | $106.0K | $0 | · | · | $144.0K | $0 | |
| Net Stock Activity | · | $6.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $19.0K | $6.0K | $5.0K | $0 | $14.0K | $0 | $29.0K | $0 | $79.0K | $0 | $106.0K | $0 | · | · | $144.0K | $0 | |
| Net Change in Cash | $1M | $-94.0K | $-6M | $8M | $1M | $1M | $-2M | $3M | $2M | $-7M | $2M | $-4M | $-1M | $6M | $-1M | $-12M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-17M | · | · | · | $-23M | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -167480.0% | -29234.6% | · | -355.1% | -510.5% | -991.4% | · | -1441.1% | -1772.3% | -324.1% | · | -719.3% | -1383.9% | -1008.5% | · | · | |
| Net Margin | -154400.0% | -27861.5% | · | -329.4% | -474.6% | -903.4% | · | -1330.1% | -1662.3% | -205.0% | · | -643.1% | -1260.1% | -929.9% | · | · | |
| EBITDA Margin | -167480.0% | -28453.8% | · | -355.1% | -510.5% | -958.8% | · | -1441.1% | -1772.3% | -315.4% | · | -719.3% | -1383.9% | -982.9% | · | · | |
| ROA | -13.3% | -10.8% | · | -8.2% | -8.6% | -9.7% | · | -10.7% | -13.5% | -6.2% | · | -7.7% | -8.0% | -7.0% | · | · | |
| ROE | -30.0% | -21.7% | · | -13.7% | -13.7% | -14.6% | · | -15.2% | -18.6% | -8.3% | · | -10.3% | -10.3% | -8.8% | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.6 | 3.5 | · | 3.6 | 3.1 | 3.1 | · | 3.2 | 4.3 | 5.7 | · | 6.7 | 7.4 | 8.1 | · | · | |
| Quick Ratio | 2.2 | 3.1 | · | 3.2 | 2.8 | 2.9 | · | 3.0 | 4.1 | 5.5 | · | 6.4 | 7.1 | 7.8 | · | · |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.56 | $10.32 | · | $16.72 | $20.24 | $1.22 | · | $1.88 | $2.24 | $2.73 | · | $3.38 | $3.75 | $4.17 | · | · | |
| Revenue / Share | $0.00 | $0.02 | · | $1.13 | $0.94 | $0.03 | · | $0.03 | $0.03 | $0.14 | · | $0.07 | $0.04 | $0.05 | · | · | |
| Cash Flow / Share | · | $-4.77 | · | · | · | $-0.35 | · | · | · | $-0.44 | · | · | · | $-0.62 | · | · | |
| Cash / Share | $6.68 | $6.04 | · | $9.25 | $5.00 | $0.22 | · | $0.24 | $0.16 | $0.11 | · | $0.24 | $0.35 | $0.39 | · | · | |
| EPS (TTM) | $-21.98 | $-21.87 | · | $-27.67 | $-31.88 | $-38.54 | · | $-19.80 | $-12.30 | $-1.66 | · | $-1.89 | $-2.04 | $-2.17 | · | $-2.56 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $6M | · | $5M | $4M | $4M | · | $10M | $11M | $11M | · | $7M | $7M | $7M | · | $5M | |
| Net Income TTM | $-29M | $-30M | · | $-43M | $-51M | $-63M | · | $-65M | $-66M | $-63M | · | $-71M | $-77M | $-81M | · | $-95M | |
| Market Cap | $7M | $8M | · | $10M | $11M | $307M | · | $496M | $574M | $1.07B | · | $790M | $972M | $1.05B | · | · | |
| P/E | -0.2 | -0.2 | · | -0.2 | -0.2 | -0.2 | · | -0.7 | -1.2 | -16.9 | · | -11.0 | -12.5 | -12.8 | · | -11.6 | |
| P/S | 1.6 | 1.2 | · | 2.0 | 2.7 | 84.3 | · | 50.7 | 51.4 | 94.3 | · | 109.7 | 143.3 | 155.9 | · | · | |
| P/B | 0.6 | 0.4 | · | 0.3 | 0.3 | 6.6 | · | 6.9 | 6.7 | 10.2 | · | 6.2 | 6.8 | 6.7 | · | · | |
| P / Tangible Book | 0.6 | 0.4 | · | 0.3 | 0.3 | 6.6 | · | 6.9 | 6.7 | 10.2 | · | 6.2 | 6.8 | 6.7 | · | 5.9 | |
| P / Cash Flow | · | -1.0 | · | · | · | -22.9 | · | · | · | -63.7 | · | · | · | -44.9 | · | · | |
| Earnings Yield | -570.9% | -541.3% | · | -520.1% | -552.5% | -481.8% | · | -152.8% | -82.0% | -5.9% | · | -9.1% | -8.0% | -7.8% | · | -8.6% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $8M | $8M | $8M | $6M | $1M |
| Margen Operativo % | -469.3% | -949.9% | -967.5% | -1576.6% | -7364.1% |
| Beneficio neto | $-33M | $-63M | $-69M | $-88M | $-99M |
| EPS Diluido | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio corriente | 3.6 | 3.2 | 5.2 | 7.5 | 8.9 |
| Ratio Rápido | 3.3 | 3.0 | 5.0 | 7.3 | 8.7 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-40M | $-61M | $-70M | $-78M | $-59M |
Propietarios institucionales (13F) 24 declarantes · $2.4M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
24
Valor en tenencia
$2.4M
Nuevas posiciones
2
Posiciones cerradas
3
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 2 (-4 vs trimestre anterior) | 3 (+1 vs trimestre anterior) | 5 (-1 vs trimestre anterior) | 4 (+1 vs trimestre anterior) | -17K |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | $530 226 | 137 721 | 22,41% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $379 706 | 98 625 | 16,05% | Acciones |
| Vivo Capital, LLC | $278 794 | 72 414 | 11,78% | Acciones |
| CITADEL ADVISORS LLC | $219 077 | 56 903 | 9,26% | Acciones |
| T3 Companies, LLC | $146 300 | 38 000 | 6,18% | Acciones |
| Board of Trustees of The Leland Stanford Junior University | $138 511 | 35 977 | 5,85% | Acciones |
| Pfizer Inc | $133 832 | 31 305 | 5,66% | Acciones |
| Lynx1 Capital Management LP | $118 580 | 30 800 | 5,01% | Acciones |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $105 875 | 27 500 | 4,48% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $73 622 | 19 119 | 3,11% | Acciones |
| Shay Capital LLC | $59 436 | 15 438 | 2,51% | Acciones |
| VANGUARD GROUP INC | $55 782 | 10 179 | 2,36% | Acciones |
| BlackRock, Inc. | $37 388 | 9 711 | 1,58% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $27 181 | 7 060 | 1,15% | Acciones |
| Nan Fung Group Holdings Ltd | $19 250 | 5 000 | 0,81% | Acciones |
| MORGAN STANLEY | $12 108 | 3 145 | 0,51% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $11 916 | 3 095 | 0,50% | Acciones |
| NewEdge Advisors, LLC | $9 740 | 2 530 | 0,41% | Acciones |
| Tower Research Capital LLC (TRC) | $6 584 | 1 710 | 0,28% | Acciones |
| UBS Group AG | $982 | 255 | 0,04% | Acciones |
| SBI Securities Co., Ltd. | $501 | 130 | 0,02% | Acciones |
| JPMORGAN CHASE & CO | $165 | 42 | 0,01% | Acciones |
| CITIGROUP INC | $158 | 41 | 0,01% | Acciones |
| BARCLAYS PLC | $23 | 6 | 0,00% | Acciones |
Activistas y propietarios del %+ 5 4 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Nan Fung Group Holdings Limited, NF Investment Holdings Limited, Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P. Ltd., Pivotal Partners Ltd, Pivotal Life Sciences Holdings Limited, Nan Fung Life Sciences Holdings Limited, Permwell Management Limited, NFLS Beta Limited, NFLS Platform Holdings Limited ×4 presentaciones | 26 de febrero de 2026 | 4,60% | Enmienda | · | SEC |
| Novo Holdings A/S ×6 presentaciones | 4 de enero de 2023 | · | Presentación inicial | · | SEC |
| Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P., Ltd. | 17 de febrero de 2021 | · | Presentación inicial | Inversión pasiva | SEC |
| Sofinnova Venture Partners X, L.P. (“SVP X”), Sofinnova Management X, L.L.C. (“SM X”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Maha Katabi (“Katabi”) | 16 de febrero de 2021 | · | Presentación inicial | Inversión pasiva | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 18 insiders · 6 directivos · 13 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| William P. Quinn | President, CEO and CFO | 18 de septiembre de 2026 S | 25 384 | 3 | 3 | $-54 705 |
| Randall C Schatzman | Chief Executive Officer | 4 de marzo de 2024 A | 1 500 | 0 | 0 | $0 |
| Grant Yonehiro | Chief Operating Officer | 18 de septiembre de 2026 S | 17 269 | 0 | 3 | $-43 834 |
| Sarah Nemec | Senior VP, Finance and PAO | 18 de septiembre de 2026 S | 17 082 | 3 | 3 | $-22 851 |
| Edith A. Perez | Chief Medical Officer | 4 de marzo de 2024 A | 37 042 | 0 | 0 | $0 |
| David Dornan | Chief Scientific Officer | 18 de febrero de 2022 A | · | 0 | 0 | $0 |
| Laura Berner | Consejero | 10 de junio de 2026 A | · | 0 | 0 | $0 |
| Jakob Dupont | Consejero | 10 de junio de 2026 A | · | 0 | 0 | $0 |
| Brian O'Callaghan | Consejero | 10 de junio de 2026 A | · | 0 | 0 | $0 |
| Nicole Onetto | Consejero | 10 de junio de 2026 A | · | 0 | 0 | $0 |
| Kathleen Laporte | Consejero | 10 de junio de 2026 A | 1 200 | 0 | 0 | $0 |
| Frank D. Lee | Consejero | 12 de junio de 2024 A | · | 0 | 0 | $0 |
| Mahendra Shah | Consejero | 12 de junio de 2024 A | 1 448 286 | 0 | 0 | $0 |
| Dr. James I. Healy | Consejero | 12 de junio de 2024 A | 2 754 437 | 0 | 0 | $0 |
| Edgar Engleman | Consejero | 30 de noviembre de 2023 S | 251 522 | 0 | 0 | $0 |
| Richard A Miller MD | Consejero | 12 de junio de 2023 A | · | 0 | 0 | $0 |
| Ashish Siri Ram Khanna | Consejero | 9 de febrero de 2021 P | 1 200 | 0 | 0 | $0 |
| Novo Holdings A/S | Propietario del 10% | 13 de julio de 2022 S | 3 703 991 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 1 ETF
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 7 060 SH | 19 de agosto de 2026 | Diario |
BOLT Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 10 analistas
COMPRA
Objetivo mediano
$7.00
+102,9%
2 20,0%
Compra fuerte
5 50,0%
Compra
3 30,0%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
3 analistas · 2026-09-28Objetivo medio $29.00 +740,6%
← Por Debajo de Todos los Objetivos
Precio Actual $3.45
Mín$5.00
Media$29.00
Máx$75.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| BOLT | $11M | -0.3 | 0.07% | -433.7% | -102.2% | · |
| IMNN | $13M | -0.6 | · | · | -298.2% | · |
| BIAF | · | · | · | · | · | · |
| ACXP | $6M | -0.5 | · | · | -180.3% | · |
| SKYE | $25M | -0.5 | · | · | -175.6% | · |
| LNAI | $513M | -2.7 | · | · | -586.4% | · |
| CELZ | · | -0.8 | -45.5% | · | · | · |
| ALZN | $5M | -0.4 | · | · | -598.1% | · |
| XBIO | · | -1.4 | 19.0% | · | · | · |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 11, 2026